Evidence map›Paper›PMID 36319895›Full record

ArticleJournal of cancer research and clinical oncology2023

Nanotechnology-augmented sonodynamic therapy and associated immune-mediated effects for the treatment of pancreatic ductal adenocarcinoma.

Marym Mohammad Hadi, Sian Farrell, Heather Nesbitt, Keith Thomas, Ilona Kubajewska, Alex Ng, Hamzah Masood, Shiv Patel, Fabiola Sciscione, Brian Davidson and 4 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Marym Mohammad Hadi *Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Sian Farrell *Biomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Heather NesbittBiomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Keith ThomasBiomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Ilona KubajewskaDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Alex NgDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Hamzah MasoodDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Shiv PatelDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Fabiola SciscioneDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Brian DavidsonDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
John F CallanBiomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Alexander J MacRobertDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.
Anthony P McHaleBiomedical Sciences Research Institute, Ulster University, Coleraine, UK.
Nikolitsa NomikouDivision of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK. n.nomikou@ucl.ac.uk.
University College London · GBUniversity of Ulster · GBFaculty (United Kingdom) · GB

Funding

Medical Research Council MC_PC_17180Wellcome Trust
6 · The paper itself

Abstract

purposeSonodynamic therapy (SDT) is emerging as a cancer treatment alternative with significant advantages over conventional therapies, including its minimally invasive and site-specific nature, its radical antitumour efficacy with minimal side effects, and its capacity to raise an antitumour immune response. The study explores the efficacy of SDT in combination with nanotechnology against pancreatic ductal adenocarcinoma.

methodsA nanoparticulate formulation (HPNP) based on a cathepsin B-degradable glutamate-tyrosine co-polymer that carries hematoporphyrin was used in this study for the SDT-based treatment of PDAC. Cathepsin B levels in BxPC-3 and PANC-1 cells were correlated to cellular uptake of HPNP. The HPNP efficiency to induce a sonodynamic effect at varying ultrasound parameters, and at different oxygenation and pH conditions, was investigated. The biodistribution, tumour accumulation profile, and antitumour efficacy of HPNP in SDT were examined in immunocompetent mice carrying bilateral ectopic murine pancreatic tumours. The immune response profile of excised tumour tissues was also examined.

resultsThe HPNP formulation significantly improved cellular uptake of hematoporphyrin for both BxPC-3 and PANC-1 cells, while increase of cellular uptake was positively correlated in PANC-1 cells. There was a clear SDT-induced cytotoxicity at the ultrasound conditions tested, and the treatment impaired the capacity of both BxPC-3 and PANC-1 cells to form colonies. The overall acoustic energy and pulse length, rather than the power density, were key in eliciting the effects observed in vitro. The SDT treatment in combination with HPNP resulted in 21% and 27% reduction of the target and off-target tumour volumes, respectively, within 24 h. A single SDT treatment elicited an antitumour effect that was characterized by an SDT-induced decrease in immunosuppressive T cell phenotypes.

conclusionSDT has significant potential to serve as a monotherapy or adjunctive treatment for inoperable or borderline resectable PDAC.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsUltrasonic TherapyAnimalsCathepsin BCell Line, TumorHematoporphyrinsMiceNanotechnologyReactive Oxygen SpeciesTissue DistributionCathepsin BHematoporphyrinsReactive Oxygen SpeciesAnticancer immune responseCathepsin BHematoporphyrinNanoparticlesPancreatic cancerSonodynamic therapy

Identifiers

PMID36319895
PMCPMC10349707
OpenAlexW4307831291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.